Close Menu

NEW YORK – Barclays on Tuesday downgraded its rating on Quest Diagnostics' stock to Equal Weight from a previous Overweight, citing reimbursement pricing pressure resulting from the Protecting Access to Medicare Act.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.